theMednetRegister

Dermatology

Pulmonology   

Questions discussed in this category

How often do you recommend ophthalmologic screening exams for patients with sarcoidosis?
4 Answers available
What is your approach to a patient with undetectable MMR titers checked prior to or during immunosuppression and a history of MMR vaccination in childhood?
Is there a role for booster vaccination and if so, how do you approach the timing when a patient is already on a biologic for immunosuppression? 
1 Answer available
In light of recent measles outbreaks in the US, would you recommend an MMR booster for an immunocompetent patients born before 1957?
6 Answers available
How do you approach treating patients who develop psoriasis while on Dupixent?
Do you start/trial them on another biologic or just rely on topical therapies?
2 Answers available
What are your vaccine recommendations while patients are on biologics?
2 Answers available
How do you approach patients who identify so strongly with being sick or with a particular diagnostic label that it makes up a significant portion of their identity?
2 Answers available
What is your preferred regimen for remission induction and maintenance in EGPA with cardiac involvement?
1 Answer available
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
2 Answers available
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
2 Answers available
Is there a subset of ANCA vasculitis patients for which you would try plasma exchange?
2 Answers available
How do you approach ongoing screening for TB in patients with a history of treated latent TB, but who have ongoing use of DMARDs and/or biologics given Quantiferon testing and PPD can remain positive?
How do you approach ongoing screening for TB in patients with history of treated latent TB, but have ongoing use of DMARDs and/or biologics given quan...
1 Answer available
What is your approach for disease activity monitoring in patients with sarcoidosis?
1 Answer available
Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?
This question is part of a collaboration with RheumMadness and is in reference to Pathogenic ANCA (RAVE Trial).
2 Answers available
Do you screen for interstitial lung disease in patients with newly diagnosed polymyositis or dermatomyositis in the absence of respiratory symptoms?
3 Answers available
Would you give checkpoint inhibitor therapy to a cancer patient with known dermatomyositis given the association of checkpoint inhibitor associated myocarditis, myasthenia gravis, and myositis?
6 Answers available
What is your preferred steroid sparing therapy in a patient experiencing a severe checkpoint inhibitor toxicity and not responding to high dose IV steroids?
2 Answers available
How would you manage subclinical ILD associated with MDA-5 Dermatomyositis?
Any indications for triple therapy in the patients with subclinical ILD associated with MDA-5 dermatomyositis?
1 Answer available
How do you approach patients with ANCA vasculitis who had partial response, but continue to have disease activity on q 6 month maintenance rituximab and remain on steroids?
Would you change rituximab maintenance dose or schedule?
1 Answer available
How do you choose between oral and IV cyclophosphamide for the treatment of ANCA-associated vasculitis?
1 Answer available
Are there AAV patients for whom you would consider combination therapy with cyclophosphamide and rituximab?
1 Answer available
What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide? 
1 Answer available
Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?
2 Answers available
How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?
1 Answer available
Are there certain subsets of ANCA vasculitis patients for whom you would consider life long maintenance therapy?
2 Answers available
How do you manage calcium and vitamin D supplementation in patients with sarcoidosis on chronic steroids?
1 Answer available
What clinical factors do you use to determine timing of on-demand dosing of rituximab in ANCA vasculitis maintenance therapy?
1 Answer available
Do you recommend on-demand versus fixed-schedule dosing for rituximab maintenance in ANCA vasculitis?
 If you use both, how do you decide which to use for a particular patient?
2 Answers available


Papers discussed in this category

N Engl J Med, 2020 Feb 13
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
The New England journal of medicine, 2010-07-15
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Medicine (Baltimore),
The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.
The New England journal of medicine, 2010-07-15
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Ann. Rheum. Dis., 2018 Apr 25
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Ann. Rheum. Dis., 2017 May 25
Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Ann. Rheum. Dis., 2018 May 03
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Kidney international reports, 2018-03
Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.
Rheumatology (Oxford),
A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
Ann Intern Med,
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
Ann Rheum Dis, 2011 Nov 29
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
Respir Med, 2012 Apr 09
The treatment of pulmonary sarcoidosis.
Am J Respir Crit Care Med,
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.
Arthritis & rheumatology (Hoboken, N.J.), 2023 Jul 24
The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS).
Am J Respir Crit Care Med, 2020 Apr 15
Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline.

Related Topics in Dermatology

Copyright © 2025 theMednet
All Rights Reserved.